Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Rules On Treatment INDs May Embolden More Patients To Ask For Trial Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency expects individual patient INDs to rise by 50 percent as a result of new regs.

You may also be interested in...



Orphan, Tropical Diseases Need Better Drug Development Guidance - Senate

A floor amendment to the Senate Agriculture/FDA appropriations bill would push FDA toward streamlining the development and regulation of drugs to treat rare diseases and neglected diseases in the developing world

Orphan, Tropical Diseases Need Better Drug Development Guidance - Senate

A floor amendment to the Senate Agriculture/FDA appropriations bill would push FDA toward streamlining the development and regulation of drugs to treat rare diseases and neglected diseases in the developing world

Expanded Access Program For Insmed’s Iplex Shows Power Of Patient Advocates At FDA

Lou Gehrig’s patients who appealed to the agency early will get access to drug; others enter a lottery system as part of a clinical trial.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel